/ Print /

PHARMACY BEST PRACTICES

Real-world results determine value-based price for specialty drugsIn an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.
Entresto may prevent death in some heart failure patientsTimely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.
Survey finds stakeholders lack understanding of biosimilarsIt is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.
Four ways healthcare executives can gain consumer trustInsurers are gaining trust while pharma moves backwards in trust. Find out why.
Effective patient messaging drives higher value healthcareMedication non-adherence is a growing issue for patients, physicians and health plans. Here’s one effective solution.
Biosimilars uptake may lag for cancer patients, physiciansBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
Experts debate best treatment for metastatic colorectal cancer patientsDe-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?
Weighing value in HER2+ breast cancer treatmentTargeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.
Patients demand access to investigational therapiesExpanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies